Psoriatic arthritis can appear in a variety of ways from nail disease to peripheral joint pain. But, there are a few hallmark signs that can send a rheumatologist or rheumatology nurse in the right direction. In this Q&A, Linda Grinnell-Merrick, NP, discusses the ins and outs of a psoriatic arthritis diagnosis.
Psoriatic arthritis can manifest in a variety of ways from nail disease to peripheral joint pain. But, there are a few hallmark signs that can point a rheumatologist or rheumatology nurse in the right direction. In a presentation given at the Rheumatology Nurses Society annual meeting in August, Linda Grinnell-Merrick, NP, an allergy, immunology, and rheumatology nurse practitioner at the University of Rochester Medical Center, discussed the treatment of psoriatic arthritis.
In this installment of the psoriatic arthritis quiz, we focus on nail pitting and onycholysis. How familiar are you with the characteristics associated with these two conditions?
Can gluten-containing food products trigger a psoriatic arthritis flare? How well does the average psoriatic arthritis patient understand their condition? Learn more in today's psoriatic arthritis quiz.
In this slideshow we provide a quick update on the latest developments the anti-TNF treatments of rheumatoid arthritis, psoriatic arthrhitis, ankylosing spondylitis and other autoimmune conditions. Among the developments includes a new surprising use for etanercept (Enbrel, Amgen).
The FDA suggests only limited use of tofacitinib to treat rheumatoid arthritis, ulcerative colitis, or psoriatic arthritis.
In today's health quiz, we highlight some of the most recent scientific advances in psoriatic arthritis research. Click here to test your knowledge.
In psoriatic arthritis, exhibiting different comorbidities may require different treatment regimens. In this installment of our monthly psoriatic arthritis quiz, we present a few different scenarios. How good are you at coming up with an effective treatment plan? Test your knowledge with this quiz.
The presence of carotid atherosclerosis in psoriasis and psoriatic arthritis patients is associated with an increased risk of having a cardiovascular event, researchers report.
A pair of phase 3 studies showed 20% symptomatic improvement in patients with psoriatic arthritis who were treated with guselkumab.
A trio of phase 3 psoriatic arthritis trials showed that 30 mg of apremilast, twice daily, increased the likelihood of achieving low disease activity or remission.
Interim results at 24 weeks show that 75.3% of patients treated with tildrakizumab achieved a 20% improvement compared to 50.6% with placebo.
Three studies presented this weekend at EULAR in Madrid suggest that being overweight or obese can heighten the severity or arthritic disease.
The overall risk of cancer in psoriatic arthritis patients who are treated with TNF inhibitors doesn’t appear to be linked to their treatment, according to a study presented EULAR this weekend.
A 24-week trial of tildrakizumab to treat the skin and joint conditions associated with psoriatic arthritis shows promise as a possible new treatment, shows a study presented at EULAR.
In this installment of our psoriatic arthritis quiz series, we focus on phenotypes unique to psoriatic arthritis. We also include a question or two on other issues that may stump you.
A FUTURE 5 trial and MAXIMIZE trial demonstrate that Cosentyx frequently stops radiographic progression and lessens axial manifestations, respectively.
Ixekizumab (Talz) was significantly more likely to both reduce disease activity by ≥50% and achieve complete skin clearance than adalimumab (Humira).
Etanercept is a safe, well-tolerated medication for treating pediatric patients with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and psoriatic arthritis, according to the results for a new study.
In April, the FDA approved the etanercept biosimilar etanercept-ykro (Eticovo, Samsung Bioepis) for the same indications as its reference product Enbrel.
In round two of our ongoing psoriatic arthritis quiz series, we focus on treatment recommendations made in the 2018 ACR/NPF psoriatic arthritis treatment guidelines. We also include a puzzler based on findings from a newly published study.
Active psoriatic arthritis and ankylosing spondylitis can lead to adverse pregnancy outcomes, which grows with corticosteroid use, a study shows.
